Altered blood-brain-barrier function in Alzheimer's disease?

Area of Science:

• Neuroscience
• Biochemistry
• Proteomics

Background:

• Alzheimer's disease (AD) and vascular dementia (VD) are leading causes of dementia.
• A definitive biological marker for antemortem differential diagnosis of AD and VD is lacking.
• Cerebrospinal fluid (CSF) protein analysis is a potential diagnostic avenue.

Purpose of the Study:

• To identify differential protein markers in CSF for distinguishing between AD and VD.
• To investigate potential alterations in CSF protein profiles associated with dementia.

Main Methods:

• Proteomic analysis of CSF samples from AD, VD, and control patients.
• Two-dimensional (2-D) electrophoresis utilizing immobilized pH gradients in the first dimension.
• Analysis of protein spot patterns to detect disease-specific changes.

Main Results:

• No specific protein changes were detected in 2-D CSF patterns that clearly distinguished AD from VD.
• A distinct spot corresponding to haptoglobin alpha-1 chains (13.5 kDa; pI ~4.6) was observed in most dementia cases.
• This finding suggests a high-molecular-weight transudate-type alteration in the blood-brain barrier, particularly frequent in AD.

Conclusions:

• The study did not identify definitive protein markers for differentiating AD and VD using 2-D electrophoresis of CSF.
• The presence of haptoglobin alpha-1 chains may indicate blood-brain barrier dysfunction in dementia patients, especially AD.
• Further research is needed to validate haptoglobin alpha-1 chains as a potential indicator of BBB integrity in neurodegenerative diseases.